Get the Stockscreener App
1.60
3.90%
0.06
Pre-market:
1.62
0.02
+1.25%
Inovio Pharmaceuticals Inc stock is traded at $1.60, with a volume of 1.72M.
It is up +3.90% in the last 24 hours and down -22.33% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.54
Open:
$1.53
24h Volume:
1.72M
Relative Volume:
1.15
Market Cap:
$109.93M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.2627
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
+0.00%
1M Performance:
-22.33%
6M Performance:
+17.65%
1Y Performance:
-15.79%
1-Day Range:
$1.50
$1.62
1-Week Range:
$1.50
$1.72
52-Week Range:
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.60 | 105.80M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO) - Seeking Alpha
Will Inovio Pharmaceuticals Inc. (GBM) stock announce special dividend2025 Investor Takeaways & Low Risk Growth Stock Ideas - Улправда
Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Why retail investors pile into Inovio Pharmaceuticals Inc. stockJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Retail Trends: Will Inovio Pharmaceuticals Inc. (GBM) stock announce special dividendMarket Performance Recap & Daily Price Action Insights - Улправда
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc.INO - PR Newswire
AstraZeneca pullback hits Inovio shares - The Pharma Letter
Looking Into Inovio Pharmaceuticals Inc's Recent Short Interest - Sahm
INOVIO announces pricing of $25M public offering - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio ... - Bluefield Daily Telegraph
San Bernardino Sun - FinancialContent
Inovio Pharmaceuticals Inc Stock Analysis and ForecastDividend Stability Analysis & Small Budget Capital Growth - Early Times
Ksolves India Limited Bounces Off Moving Average SupportStock Correlation Metrics & Superior Return Stocks - earlytimes.in
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
FDA sets 2026 decision clock for INOVIO’s rare disease therapy - MSN
U.S., U.K. Strike Drug Pricing Deal Aimed at Ending Transatlantic Imbalance - MyChesCo
INOVIO Reports Inducement Grant Under Inducement Plan - Eastern Progress
RSI Check: Will Inovio Pharmaceuticals Inc GBM stock announce special dividendEarnings Recap Summary & Free Verified High Yield Trade Plans - moha.gov.vn
FDA Sets 2026 Decision Clock for INOVIO’s Rare Disease Therapy - MyChesCo
Inovio respiratory DNA drug candidate shows promise in early trial - MSN
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Inovio drops as respiratory papillomatosis asset denied accelerated review - MSN
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Jefferies reiterates Hold on Inovio stock amid FDA review uncertainty By Investing.com - Investing.com Canada
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - FinancialContent
Inovio stock plummets 25% after FDA denies accelerated review for lead drug candidate - The Business Journals
INOVIO’s DNA therapy for rare throat disease gets FDA review - Indian Pharma Post
Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107 - Investing.com Canada
User - FinancialContent
FDA accepts Inovio’s BLA for INO-3107 review - MSN
FDA setback gives Inovio a headache - The Pharma Letter
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Why Is Inovio Pharma Stock Sinking Monday?Inovio Pharmaceuticals (NASDAQ:INO) - Benzinga
Inovio (INO) Shares Plummet 21% After FDA Review Update - GuruFocus
Inovio stock tumbles after FDA questions accelerated approval path By Investing.com - Investing.com Australia
Inovio stock tumbles after FDA questions accelerated approval path - Investing.com India
Inovio Pharmaceuticals Inc: Not Currently Pla - 富途牛牛
EBIT per share of Inovio Pharmaceuticals, Inc. – BIVA:INO - TradingView — Track All Markets
INOVIO (INO) Seeks Accelerated Approval for INO-3107 from FDA - GuruFocus
INOVIO Pharmaceuticals, Inc. Announces FDA Acceptance of BLA for INO-3107 - TradingView — Track All Markets
FDA accepts INOVIO’s BLA for RRP treatment, sets October 2026 target date - Investing.com UK
Rare throat disease may get a new non-surgical treatment option - Stock Titan
Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug - Sahm
INOVIO Issues Equity Award to New Hire as It Rebuilds for Its Next Act - MyChesCo
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight - MyChesCo
INO (Inovio Pharmaceuticals) EV-to-OCF : -1.30 (As of Dec. 22, 2025) - GuruFocus
Sentiment Review: Is AMODW stock attractive for long term wealth buildingGap Down & Expert Approved Momentum Ideas - moha.gov.vn
Published on: 2025-12-22 07:17:12 - moha.gov.vn
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):